Xavier Paolettí

8.6k total citations · 1 hit paper
158 papers, 4.1k citations indexed

About

Xavier Paolettí is a scholar working on Statistics and Probability, Oncology and Cancer Research. According to data from OpenAlex, Xavier Paolettí has authored 158 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Statistics and Probability, 56 papers in Oncology and 36 papers in Cancer Research. Recurrent topics in Xavier Paolettí's work include Statistical Methods in Clinical Trials (57 papers), Cancer Genomics and Diagnostics (30 papers) and Health Systems, Economic Evaluations, Quality of Life (25 papers). Xavier Paolettí is often cited by papers focused on Statistical Methods in Clinical Trials (57 papers), Cancer Genomics and Diagnostics (30 papers) and Health Systems, Economic Evaluations, Quality of Life (25 papers). Xavier Paolettí collaborates with scholars based in France, United Kingdom and Belgium. Xavier Paolettí's co-authors include Christophe Le Tourneau, John O’Quigley, Vincent Servois, Marie Alt, Delphine Loirat, Tomasz Burzykowski, Birgit Geoerger, Virginia Palomar Coloma, Jérôme Fayette and Esma Saâda-Bouzid and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Xavier Paolettí

146 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

2017 449 citations Esma Saâda-Bouzid, Andy Karabajakian et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xavier Paolettí France	37	1.4k	906	707	698	685	158	4.1k
Gina R. Petroni United States	42	2.7k 1.9×	335 0.4×	1.2k 1.6×	1.7k 2.5×	520 0.8×	161	6.0k
Alexia Iasonos United States	51	3.2k 2.3×	662 0.7×	2.3k 3.2×	1.6k 2.3×	1.4k 2.0×	266	10.3k
Lucinda Billingham United Kingdom	37	2.1k 1.5×	165 0.2×	1.2k 1.7×	861 1.2×	512 0.7×	138	5.0k
Simon Wandel Switzerland	24	512 0.4×	318 0.4×	441 0.6×	696 1.0×	111 0.2×	37	4.2k
Simone Mathoulin‐Pélissier France	39	2.0k 1.4×	260 0.3×	1.6k 2.3×	394 0.6×	756 1.1×	179	5.9k
Yann De Rycke France	30	1000 0.7×	170 0.2×	959 1.4×	525 0.8×	970 1.4×	105	3.3k
Anne I. Goldman United States	36	1.2k 0.9×	264 0.3×	557 0.8×	676 1.0×	220 0.3×	73	5.1k
Marcy Winget United States	26	1.8k 1.3×	122 0.1×	573 0.8×	1.2k 1.7×	451 0.7×	102	4.7k
Julien Péron France	28	1.0k 0.7×	244 0.3×	453 0.6×	207 0.3×	240 0.4×	121	2.1k
Émilie Lanoy France	30	3.2k 2.3×	270 0.3×	743 1.1×	996 1.4×	236 0.3×	85	5.3k

Countries citing papers authored by Xavier Paolettí

Since Specialization

Citations

This map shows the geographic impact of Xavier Paolettí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Paolettí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Paolettí more than expected).

Fields of papers citing papers by Xavier Paolettí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Paolettí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Paolettí. The network helps show where Xavier Paolettí may publish in the future.

Co-authorship network of co-authors of Xavier Paolettí

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Paolettí. A scholar is included among the top collaborators of Xavier Paolettí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Paolettí. Xavier Paolettí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dupain, Célia, Grégoire Marret, Xavier Paolettí, et al.. (2024). Pan‐cancer evaluation of tumor‐infiltrating lymphocytes and programmed cell death protein ligand‐1 in metastatic biopsies and matched primary tumors. The Journal of Pathology. 264(2). 186–196.

Balaya, Vincent, Benedetta Guani, Paolo Zola, et al.. (2023). Survival after sentinel lymph node biopsy for early cervical cancers: a systematic review and meta-analysis. International Journal of Gynecological Cancer. 33(12). 1853–1860. 9 indexed citations

Roustit, Matthieu, Silvy Laporte, Philippe Barthélémy, et al.. (2022). Les essais plateformes. Therapies. 78(1). 19–28. 3 indexed citations

Roustit, Matthieu, Silvy Laporte, Philippe Barthélémy, et al.. (2022). Platform trials. Therapies. 78(1). 29–38. 13 indexed citations

Pasqualini, Claudia, Lydie Cassard, Nicolás André, et al.. (2021). Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium. European Journal of Cancer. 150. 53–62. 36 indexed citations

Roumiguié, M., Xavier Paolettí, Y. Neuzillet, et al.. (2021). Apalutamide, Darolutamide and Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Meta-Analysis. Future Oncology. 17(14). 1811–1823. 11 indexed citations

Mimoun, Camille, Xavier Paolettí, Thomas Gaillard, et al.. (2021). Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN group. PLoS ONE. 16(10). e0258783–e0258783. 3 indexed citations

Héquet, Delphine, et al.. (2021). Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review. Cancer Medicine. 10(15). 5203–5217. 24 indexed citations

Morscher, Raphael J., Pablo Berlanga, Lynley V. Marshall, et al.. (2021). First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial. European Journal of Cancer. 157. 268–277. 24 indexed citations

10.

Oba, Koji, Xavier Paolettí, Yung‐Jue Bang, et al.. (2020). Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials.. Journal of Clinical Oncology. 38(15_suppl). e16506–e16506. 1 indexed citations

11.

Jaki, Thomas, A. Gordon, Luc Bijnens, et al.. (2018). A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics. 17(5). 593–606. 4 indexed citations

12.

Mozgunov, Pavel, Thomas Jaki, & Xavier Paolettí. (2018). Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. Journal of Biopharmaceutical Statistics. 29(2). 359–377. 9 indexed citations

13.

Saâda-Bouzid, Esma, Andy Karabajakian, Virginia Palomar Coloma, et al.. (2017). Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology. 28(7). 1605–1611. 449 indexed citations breakdown →

14.

Anota, Amélie, Mathieu Boulin, Tienhan Sandrine Dabakuyo‐Yonli, et al.. (2016). An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. BMJ Open. 6(6). e010696–e010696. 11 indexed citations

15.

Paolettí, Xavier, Bernard Asselain, Maud Kamal, et al.. (2015). Design and statistical principles of the SHIVA trial.. PubMed. 4(3). 32–32. 1 indexed citations

16.

Paolettí, Xavier, Christophe Le Tourneau, Jaap Verweij, et al.. (2014). Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. European Journal of Cancer. 50(12). 2050–2056. 60 indexed citations

17.

Tourneau, C. Le, Maud Kamal, Olivier Trédan, et al.. (2013). Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Refractory Cancer Patients: Shiva Design. Annals of Oncology. 24. i36–i36.

18.

Beurtheret, Sylvain, Pierre Mordant, Xavier Paolettí, et al.. (2012). Emergency circulatory support in refractory cardiogenic shock patients in remote institutions: a pilot study (the cardiac-RESCUE program). European Heart Journal. 34(2). 112–120. 164 indexed citations

19.

Paolettí, Xavier, Benoît Baron, Patrick Schöffski, et al.. (2006). Using the continual reassessment method: Lessons Learned from an EORTC phase I dose finding study. European Journal of Cancer. 42(10). 1362–1368. 21 indexed citations

20.

Boyer, Patrick, P. Djian, P. Christel, Xavier Paolettí, & R. Degeorges. (2004). Fiabilité de l’arthromètre KT-1000 pour la mesure de la laxité antérieure du genou. Revue de Chirurgie Orthopédique et Réparatrice de l Appareil Moteur. 90(8). 757–764. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact